1. Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors
   Jawad Bilal et al, 2019, JAMA Network Open CrossRef
2. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials
   Milène Séauve et al, 2024, Joint Bone Spine CrossRef
3. Axiale Spondyloarthritis – ein Fallbeispiel aus ärztlicher Sicht
   Verena Schmitt et al, 2021, MSK – Muskuloskelettale Physiotherapie CrossRef
4. Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry
   Proton Rahman et al, 2020, BMC Rheumatology CrossRef
5. Risk of infection associated with anti-TNF-α therapy
   Mario Fernández-Ruiz et al, 2018, Expert Review of Anti-infective Therapy CrossRef
6. Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process
   Rosario García-Vicuña et al, 2023, Rheumatology and Therapy CrossRef
7. Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study
   Bora Nam et al, 2024, BMC Rheumatology CrossRef
8. Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study
   Jakub Wroński et al, 2019, International Journal of Clinical Pharmacy CrossRef
9. Aktuelle Therapie der axialen Spondyloarthritis
   U. Kiltz et al, 2020, Zeitschrift für Rheumatologie CrossRef
10. Certolizumab pegol in the treatment of axial spondyloarthritis
    Elizabeth Anderson et al, 2024, Immunotherapy CrossRef
11. Langfassung zur S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen, Update 2019
    null null et al, 2019, Zeitschrift für Rheumatologie CrossRef
12. Safety and efficacy of pharmacological treatments for axial spondyloarthritis
    Chen Dong et al, 2023, International Journal of Rheumatic Diseases CrossRef
13. Effects of Tumor Necrosis Factor-alpha Inhibitors on the Incidence of Tuberculosis
    Hyun Jin Park et al, 2018, Korean Journal of Clinical Pharmacy CrossRef
14. Adverse events of tumor necrosis factor alpha inhibitors for the treatment of ankylosing spondylitis: A meta-analysis of randomized, placebo-controlled trials
    Haihuan Feng et al, 2023, Frontiers in Pharmacology CrossRef
15. Applications of single-cell RNA sequencing in rheumatoid arthritis
    Marxa L. Figueiredo, 2024, Frontiers in Immunology CrossRef
16. Risk of nonpulmonary infections requiring hospitalization in spondyloarthritis
    Ho Yin Chung et al, 2022, Immunity, Inflammation and Disease CrossRef
17. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?
    Jakub Wroński et al, 2019, The Journal of Clinical Pharmacology CrossRef
18. Ankylosing spondylitis and mesenchymal stromal/stem cell therapy: a new therapeutic approach
    Kamal Abdolmohammadi et al, 2019, Biomedicine & Pharmacotherapy CrossRef
19. Adalimumab (Humira®) Induced Recurrent Peritonsillar Abscess in A Patient Received Three Different Anti-TNF Therapies: A Case Report
    Sevilay Vural et al, 2023, Indian Journal of Otolaryngology and Head & Neck Surgery CrossRef
20. The frequency and structure of comorbid infections in patients with spondyloarthritis (preliminary own data)
    M. M. Baranova et al, 2021, Meditsinskiy sovet = Medical Council CrossRef
21. The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study
    Johannes Nossent et al, 2022, Rheumatology and Therapy CrossRef